Seribantumab companion diagnostic - Merrimack

Drug Profile

Seribantumab companion diagnostic - Merrimack

Alternative Names: MM 121 companion diagnostic; MM 121 companion diagsnotic - Leica Biosystems/Merrimack Pharmaceuticals; Seribantumab companion diagnostic - Leica Biosystems/Merrimack Pharmaceuticals

Latest Information Update: 23 May 2016

Price : $50

At a glance

  • Originator Merrimack Pharmaceuticals
  • Class Diagnostic agents
  • Mechanism of Action
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Solid tumours

Most Recent Events

  • 17 May 2016 Final efficacy data from a phase II trial in Breast cancer (Diagnosis) released by Merrimack
  • 14 Apr 2016 Leica Biosystems is collaborating with Merrimack Biosystems for the development of companion diagnostics
  • 31 Mar 2015 Phase II development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top